Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction

Chinese Medical Journal

Volumn 125, Issue 10, 2012, Pages 1713-1719

  Zhang, Hang ^a   Tian, Nai Liang ^a   Hu, Zuo Ying ^a   Wang, Feng ^a   Chen, Liang ^a   Zhang, Yao Jun ^a   Chen, Shao Liang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Acute myocardial infarction; Adenosine; Infarct size; Left ventricular function

Indexed keywords

ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ADENOSINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE MB; GLYCERYL TRINITRATE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRONCHOSPASM; CONTROLLED STUDY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE PERFUSION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VOMITING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HEART INFARCTION; MIDDLE AGED; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADENOSINE; AGED; ANGIOPLASTY, BALLOON, CORONARY; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; VENTRICULAR FUNCTION, LEFT;

EID: 84866694194     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn     Document Type: Article

References (24)

1. Kloner RA. Does reperfusion injury exist in humans. J Am Coll Cardiol 1993; 21: 537-545.
2. De Luca G, van't Hof AW, de Boer MJ, Hoorntje JC, Gosselink AT, Dambrink JH. Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure. Circulation 2004; 109: 958-961.
3. Mubagwa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 2001; 52: 25-39.
4. Hill RJ, Oleynek JJ, Magee W, Knight DR, Tracey WR. Relative importance of adenosine A1 and A3 receptors in mediating physiological or pharmacological protection from ischemic myocardial injury in the rabbit heart. J Mol Cell Cardiol 1998; 30: 579-585.
5. Yaar R, Jones MR, Chen JF, Ravid K. Animal models for the study of adenosine receptor. J Cell Physiol 2005; 202: 9-20.
6. Vander Heide RS, Reimer KA. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res 1996; 31: 711-718.
7. Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, et al. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699-1705.
8. Claeys MJ, Bosmans J, De Ceuninck M, Beunis A, Vergauwen W, Vorlat A, et al. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 9-13.
9. Assali AR, Sdringola S, Ghani M, Denkats AE, Yepes A, Hanna GP, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheter Cardiovasc Interv 2000; 51: 27-31.
10. Quintana M, Hjemdahl P, Sollevi A, Kahan T, Edner M, Rehnqvist N, et al. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol 2003; 59: 1-9.
11. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34: 1711-1720.
12. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW, AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45: 1775-1780.
13. Kopecky SL, Aviles RJ, Bell MR, Lobl JK, Tipping D, Frommell G, et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J 2003; 146: 146-152.
14. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101: 2154-2159.
15. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-636.
16. Smith SC, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC-AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 2001; 37: 2215-2239.
17. Kern MJ, Moore JA, Aguirre FV, Bach RG, Caracciolo EA, Wolford T, et al. Determination of angiographic (TIMI grade) blood flow by intracoronary Doppler flow velocity during acute myocardial infarction. Circulation 1996; 94:1545-1552.
18. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105: 1909-1913.
19. Nathoe HM, Koerselman J, Buskens E, van Dijk D, Stella PR, Plokker TH, et al. Determinants and prognostic significance of collaterals in patients undergoing coronary revascularization. Am J Cardiol 2006; 98: 31-35.
20. Anagnostopoulos C, Harbinson M, Kelion A, Kundley K, Loong CY, Notghi A, et al. Procedure guidelines for radionuclide myocardial perfusion imaging. Heart 2004; 90 (Suppl I): i1-i10.
21. Møller JE, Pellikka PA, Hillis GS, Oh JK. Prognostic importance of diastolic function and filling pressure in patients with acute myocardial infarction. Circulation 2006; 114: 438-444.
22. Reffelmann T, Kloner RA. The "no-reflow" phenomenon: basic science and clinical correlates. Heart 2002; 87: 162-168.
23. Cappello S, Angelone T, Tota B, Pagliaro P, Penna C, Rastaldo R, et al. Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am J Physiol Heart Circ Physiol 2007; 293: H719-H727.
24. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 2006; 24: 116-147.